NVDA
NVIDIA
-- 134.250 AVGO
Broadcom
-- 224.800 TSLA
Tesla
-- 436.230 AMD
Advanced Micro Devices
-- 126.910 PLTR
Palantir
-- 76.070 
NEWS SATURDAY
Updated Clinical Results: ALLELE study, a pivotal Phase 3 clinical trial evaluating tabelecleucel (tab-cel) in patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy.
The study demonstrated a statistically significant overall response rate (ORR) of 49%, with a median duration of response of 23 months ano nedian overall survival of 18.4 months. The safety profile was favorable, with no reports of tumor flare reactions, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome.
These findings support tabelecleucel as a potential therapeutic option for patients with relapsed or refractory EBV+ PTLD, These findings support tabelecleucel as a potential therapeutic option for patients with relapsed or refractory EBV+ PTLD,
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment